Beta
311244

PREPARATION AND EVALUATION OF SUSTAINED RELEASE MATRIX FORMULATIONS OF VORICONAZOLE

Article

Last updated: 23 Dec 2024

Subjects

-

Tags

Pharmaceutics and industrial pharmacy

Abstract

Voriconazole is a triazole antifungal with a half-life of 1.7 hours and 96% oral bioavailability. The oral route is the most popular of drug delivery routes. However, there are a few limitations to the traditional dosage form, for instance, fluctuations in plasma drug level.  Sustained drug delivery system overcomes these limitations; it helps to maintain stable plasma drug concentrations by decreasing drug r elease and extending the duration of the effect. The main purpose of this study was to formulate voriconazole sustained release dosage form to enhance efficacy, decrease dose frequency, decrease its side effects, and improve patient compliance. The study explored various formulations for producing the sustained-release (S.R) dosage form, as well as assessed the drug's release kinetics and its stability. Methodology: Fourier-transform Infrared Spectroscopy was used to investigate drug-polymer compatibility. The micromeritics of voriconazole powder and its blends were evaluated. Different sustained release tablets were formulated utilizing a wet granulation process and acrylic polymers (Eudragit) i.e., Eudragit RL100 and RS100 alone and as mixtures with different ratios, in different concentrations. In-vitro drug release of formulae was performed for 24 hours. The formula with desired control of drug release and complied with dissolution specifications for SR dosage forms was further evaluated for its stability by storage for 3 months at 30o C and 40o C and 75% relative humidity. Results: no interaction was observed between voriconazole and polymers using FTIR. The powder blends micromeritics were found to be in accordance with the specification. Tablets showed release from 37.29 to 76 % up to 24 hr using USP type I technique. It was found that as polymer concentration increased, the drug release from tablet decreased. The selected formulation F13 which containing 5% of Eudragit RL100:RS100 at a ratio of (10:1) was found to be stable.  Conclusion: The obtained data concluded that the F13 formula gave more prominent S.R effect than using Eudragit RL100 or RS 100 alone.

DOI

10.21608/ajps.2023.311244

Keywords

Voriconazole, Sustained Release Matrix Tablets, Micromeritics, Eudragit RS100, Eudragit RL100

Authors

First Name

Shereen

Last Name

Abd El Gawad

MiddleName

-

Affiliation

Egyptian Drug Authority EDA, Egypt

Email

shereen.abdelgawad@aucegypt.edu

City

-

Orcid

-

First Name

Maha

Last Name

Marzouk

MiddleName

-

Affiliation

Department of Pharmaceutics and Pharmaceutical Technology, Faculty of Pharmacy (Girls); Al- Azhar University, Egypt.

Email

-

City

-

Orcid

-

First Name

Amal

Last Name

Ammar

MiddleName

-

Affiliation

Department of Pharmaceutics and Pharmaceutical Technology, Faculty of Pharmacy (Girls); Al- Azhar University, Egypt.

Email

-

City

-

Orcid

-

Volume

67

Article Issue

1

Related Issue

42767

Issue Date

2023-03-01

Receive Date

2023-08-05

Publish Date

2023-03-01

Page Start

19

Page End

36

Print ISSN

1110-1644

Online ISSN

2535-1958

Link

https://ajps.journals.ekb.eg/article_311244.html

Detail API

https://ajps.journals.ekb.eg/service?article_code=311244

Order

311,244

Type

Original Article

Type Code

518

Publication Type

Journal

Publication Title

Al-Azhar Journal of Pharmaceutical Sciences

Publication Link

https://ajps.journals.ekb.eg/

MainTitle

PREPARATION AND EVALUATION OF SUSTAINED RELEASE MATRIX FORMULATIONS OF VORICONAZOLE

Details

Type

Article

Created At

23 Dec 2024